Drug Profile

ZHB 114

Alternative Names: ZHB-114; ZHB-C002

Latest Information Update: 25 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Jul 2025 Jiangsu ZonHon Biopharma Institute has patents pending for ZHB 114 in USA and China (Jiangsu ZonHon Biopharma Institute pipeline, July 2025)
23 Jul 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral) before July 2025 (Jiangsu ZonHon Biopharma Institute pipeline, July 2025)
23 Jun 2025 US FDA approves IND application of ZHB 114 for Solid tumours (Jiangsu ZonHon Biopharma Institute website, June 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com